CSPC’s bispecific fusion protein drug JMT-106 gains US IND clearance for GPC3-positive solid tumors

Jan. 16, 2024

CSPC Pharmaceutical Group Ltd. has announced FDA approval of an IND application for JMT-106, a bispecific fusion protein drug, for glypican-3 (GPC3)-positive solid tumors.

BioWorld Science Regulatory Cancer Immuno-oncology FDA IND

Today's news in brief

BioWorld

BioWorld briefs for Feb. 18, 2025.

European VCs optimistic for med-tech exit opportunities in 2025

BioWorld MedTech

To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Feb. 14, 2025

European VCs bullish on med-tech investments in 2025

BioWorld MedTech

European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...

3D illustration of acute myeloid leukemia cells

Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML

BioWorld

Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...